Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 18, 2025
Product Development

2025 catalysts: New mechanisms in obesity, neurology, ophthalmology

New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD
BioCentury | Oct 7, 2024
Distillery Therapeutics

An ATP1A1 stabilizer for anxiety

BioCentury | Jun 19, 2024
Product Development

Clinical Report: Zentalis hold resurfaces WEE1 safety concerns

Plus data from BioNTech, MediLink, Nurix, Aerovate and more
BioCentury | Apr 24, 2024
Product Development

Clinical report: Sanofi data advances pair of autoimmune disease mechanisms

Plus: Neurocrine hits in Phase II depression study and updates from Cerevel, Sage, Ventus, Lilly and AbbVie
BioCentury | Mar 26, 2024
Distillery Therapeutics

Inhibiting MS4A7 for MASH

BioCentury | Mar 18, 2024
Product Development

Treating obesity by quelling inflammation in the brain

How NLRP3 inhibitors could extend durability and enhance CV benefits over GLP-1 therapies alone
BioCentury | Mar 12, 2024
Product Development

Clinical report: takeaways from Amylyx’s ALS journey

Plus: A comeback for Regulus? And updates from Acadia, MoonLake, Ventyx, Acelyrin, Sanofi and more
BioCentury | Mar 9, 2024
Finance

Public equity report: Boundless to test IPO appetite as follow-ons continue to deliver

Public offerings by Akero, BridgeBio, RegenxBio, Apogee, plus PIPEs for Ventyx and BiomX-Adaptive Phage union
BioCentury | Feb 2, 2024
Finance

VC roundup: New funds for TCG and Seroba, rounds for Cour and Aqemia

Plus fresh cash for Halia and Neophore, and a new spinout from venture-backed Cumulus Oncology
Items per page:
1 - 10 of 143